chemotherapeutic regimens fail to achieve high cure rates for cancer the failure relates to the gompertzian acceleration or reduction in cancer cell cycle time induced by the chemotherapeutic reduction of tumor size which in turn results in the cancer 39 s lack of phase synchronicity to subsequent administrations of the phase specific chemotherapeutic the invention discloses how to avoid this failure in endocrine dependent cancers by using endocrine blockers between chemotherapeutic administrations to halt the cancer cells from passing the s phase and then using endocrine hormones to restart and accelerate s phase progression in conjunction with administration of appropriate phase specific chemotherapeutic application_number US 99142701 A description the treatments disclosed below involve administration of endocrine hormones in conjunction with administration of phase specific chemotherapeutics materials and methods for achieving this are described below a large variety of estrogen progesterone or testosterone hormones are commercially available and are listed in the physician 39 s desk reference pdr incorporated herein by reference as an example for cancers exhibiting estrogen receptors one could use estrogens comprising estradiol tablets mylan or watson premarin u00ae intravenous estrogens wyeth ayrest premarin u00ae estrogen tablets wyeth ayrest estratab u00ae esterified estrogens tablets solvay any one of several transdermal estrogen delivery systems or any other.